{"pmid":32392859,"title":"SARS-CoV-2 Infection with Different Radiological Insights.","text":["SARS-CoV-2 Infection with Different Radiological Insights.","Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) is a novel viral infection characterized by several symptoms range from mild to severe clinical conditions that could lead to death. We report two different radiological findings on computed tomography (CT) in two patients affected by SARS-CoV-2: a lung acute embolism (APE) in the first case and a radiological picture of acute respiratory distress syndrome (ARDS) in the second case. This is an important issue to be identified in order to provide more specific therapy earlier, including both antiviral and anti-inflammatory drugs associated with anti anticoagulant therapy.","Diagnostics (Basel)","Brogna, Barbara","Brogna, Claudia","Martino, Alberigo","Minichiello, Stefana","Romeo, Domenico M","Romano, Paolo","Bignardi, Elio","Mazza, Emerico Maria","Musto, Lanfranco","32392859"],"abstract":["Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) is a novel viral infection characterized by several symptoms range from mild to severe clinical conditions that could lead to death. We report two different radiological findings on computed tomography (CT) in two patients affected by SARS-CoV-2: a lung acute embolism (APE) in the first case and a radiological picture of acute respiratory distress syndrome (ARDS) in the second case. This is an important issue to be identified in order to provide more specific therapy earlier, including both antiviral and anti-inflammatory drugs associated with anti anticoagulant therapy."],"journal":"Diagnostics (Basel)","authors":["Brogna, Barbara","Brogna, Claudia","Martino, Alberigo","Minichiello, Stefana","Romeo, Domenico M","Romano, Paolo","Bignardi, Elio","Mazza, Emerico Maria","Musto, Lanfranco"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32392859","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/diagnostics10050283","keywords":["acute respiratory distress syndrome","lung acute embolism","severe acute respiratory syndrome-coronavirus-2"],"topics":["Case Report"],"weight":1,"_version_":1666627827955400704,"score":9.490897,"similar":[{"pmid":32471278,"title":"Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.","text":["Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.","At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention.","Int J Mol Sci","Orienti, Isabella","Gentilomi, Giovanna Angela","Farruggia, Giovanna","32471278"],"abstract":["At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention."],"journal":"Int J Mol Sci","authors":["Orienti, Isabella","Gentilomi, Giovanna Angela","Farruggia, Giovanna"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471278","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21113812","keywords":["covid-19","adjuvant treatment","anti-inflammatory","antiviral environment","fenretinide","pulmonary delivery"],"topics":["Treatment"],"weight":1,"_version_":1668255193274253313,"score":125.342926},{"pmid":32502524,"pmcid":"PMC7264941","title":"Tocilizumab administration in a refractory case of COVID-19.","text":["Tocilizumab administration in a refractory case of COVID-19.","Novel coronavirus (COVID-19) pneumonia as a pandemic disease leads to acute respiratory distress syndrome (ARDS), acute cardiac injury, multi organ failure, and shock. In the absence of specific treatment for COVID-19, there is an urgent need to find the alternative treatments to manage this pandemic. Pathophysiological studies have demonstrated the role of inflammatory mediators in COVID-19 pneumonia. It appears that imbalances between inflammatory and anti-inflammatory cytokines are the probable underlying mechanism. Since, there is no specific treatment for the inflammatory phase of COVID-19 pneumonia, consideration of treatments, such as tocilizumab, as salvage therapy is necessary. Here, we reported a challenging case of COVID-19 who was successfully treated with tocilizumab.","Int J Antimicrob Agents","Dastan, Farzaneh","Nadji, Seyed Alireza","Saffaei, Ali","Tabarsi, Payam","32502524"],"abstract":["Novel coronavirus (COVID-19) pneumonia as a pandemic disease leads to acute respiratory distress syndrome (ARDS), acute cardiac injury, multi organ failure, and shock. In the absence of specific treatment for COVID-19, there is an urgent need to find the alternative treatments to manage this pandemic. Pathophysiological studies have demonstrated the role of inflammatory mediators in COVID-19 pneumonia. It appears that imbalances between inflammatory and anti-inflammatory cytokines are the probable underlying mechanism. Since, there is no specific treatment for the inflammatory phase of COVID-19 pneumonia, consideration of treatments, such as tocilizumab, as salvage therapy is necessary. Here, we reported a challenging case of COVID-19 who was successfully treated with tocilizumab."],"journal":"Int J Antimicrob Agents","authors":["Dastan, Farzaneh","Nadji, Seyed Alireza","Saffaei, Ali","Tabarsi, Payam"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502524","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijantimicag.2020.106043","keywords":["acute respiratory distress syndrome","covid-19","coronavirus","interleukin-6, tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1668890966424027136,"score":125.01969},{"pmid":32112966,"pmcid":"PMC7110436","title":"2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation.","text":["2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation.","INTRODUCTION: Several recent case reports have described common early chest imaging findings of lung pathology caused by 2019 novel Coronavirus (SARS-COV2) which appear to be similar to those seen previously in SARS-CoV and MERS-CoV infected patients. OBJECTIVE: We present some remarkable imaging findings of the first two patients identified in Italy with COVID-19 infection travelling from Wuhan, China. The follow-up with chest X-Rays and CT scans was also included, showing a progressive adult respiratory distress syndrome (ARDS). RESULTS: Moderate to severe progression of the lung infiltrates, with increasing percentage of high-density infiltrates sustained by a bilateral and multi-segmental extension of lung opacities, were seen. During the follow-up, apart from pleural effusions, a tubular and enlarged appearance of pulmonary vessels with a sudden caliber reduction was seen, mainly found in the dichotomic tracts, where the center of a new insurgent pulmonary lesion was seen. It could be an early alert radiological sign to predict initial lung deterioration. Another uncommon element was the presence of mediastinal lymphadenopathy with short-axis oval nodes. CONCLUSIONS: Although only two patients have been studied, these findings are consistent with the radiological pattern described in literature. Finally, the pulmonary vessels enlargement in areas where new lung infiltrates develop in the follow-up CT scan, could describe an early predictor radiological sign of lung impairment.","Int J Infect Dis","Albarello, Fabrizio","Pianura, Elisa","Di Stefano, Federica","Cristofaro, Massimo","Petrone, Ada","Marchioni, Luisa","Palazzolo, Claudia","Schinina, Vincenzo","Nicastri, Emanuele","Petrosillo, Nicola","Campioni, Paolo","Eskild, Petersen","Zumla, Alimuddin","Ippolito, Giuseppe","32112966"],"abstract":["INTRODUCTION: Several recent case reports have described common early chest imaging findings of lung pathology caused by 2019 novel Coronavirus (SARS-COV2) which appear to be similar to those seen previously in SARS-CoV and MERS-CoV infected patients. OBJECTIVE: We present some remarkable imaging findings of the first two patients identified in Italy with COVID-19 infection travelling from Wuhan, China. The follow-up with chest X-Rays and CT scans was also included, showing a progressive adult respiratory distress syndrome (ARDS). RESULTS: Moderate to severe progression of the lung infiltrates, with increasing percentage of high-density infiltrates sustained by a bilateral and multi-segmental extension of lung opacities, were seen. During the follow-up, apart from pleural effusions, a tubular and enlarged appearance of pulmonary vessels with a sudden caliber reduction was seen, mainly found in the dichotomic tracts, where the center of a new insurgent pulmonary lesion was seen. It could be an early alert radiological sign to predict initial lung deterioration. Another uncommon element was the presence of mediastinal lymphadenopathy with short-axis oval nodes. CONCLUSIONS: Although only two patients have been studied, these findings are consistent with the radiological pattern described in literature. Finally, the pulmonary vessels enlargement in areas where new lung infiltrates develop in the follow-up CT scan, could describe an early predictor radiological sign of lung impairment."],"journal":"Int J Infect Dis","authors":["Albarello, Fabrizio","Pianura, Elisa","Di Stefano, Federica","Cristofaro, Massimo","Petrone, Ada","Marchioni, Luisa","Palazzolo, Claudia","Schinina, Vincenzo","Nicastri, Emanuele","Petrosillo, Nicola","Campioni, Paolo","Eskild, Petersen","Zumla, Alimuddin","Ippolito, Giuseppe"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32112966","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1016/j.ijid.2020.02.043","keywords":["covid-19","ct-scan","crazy-paving","enlarged pulmonary vessels","ground glass opacities","sars-cov2"],"locations":["Italy","Wuhan","China","Italy"],"countries":["Italy","China"],"countries_codes":["ITA|Italy","CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1666138492851191808,"score":123.8466},{"pmid":32398268,"title":"Lung ultrasound in the monitoring of COVID-19 infection.","text":["Lung ultrasound in the monitoring of COVID-19 infection.","INTRODUCTION: Coronavirus disease 2019 (COVID-19) is a highly contagious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pneumonia and acute respiratory distress syndrome (ARDS) are the most common severe complications. There is growing evidence regarding the imaging findings of COVID-19 in chest X-rays and computed tomography (CT) scans; however, their availability to clinical staff in this pandemic outbreak might be compromised. At this moment, the role of lung ultrasound (LUS) has yet to be explored. The purpose of this case report is to describe the natural course of the disease in mild infection managed at home. CASE REPORT: We report a 35-year-old man with recently diagnosed COVID-19 infection. Clinical examination was unremarkable. The diagnosis of mild disease was made clinically which was later reaffirmed by LUS after identifying a bilateral small pleural effusion and a thickened pleural line. During follow up, subpleural consolidations appeared before symptoms slightly aggravated (cough, tiredness and fever). The patient's condition improved after adjustment of therapy at home. CONCLUSION: LUS is an excellent tool in the characterisation of COVID-19 infection and is more available than CT or X-ray. We emphasise the utility and the opportunity that LUS presents in some clinical scenarios, like this COVID-19 pandemic, and how it may serve as a monitoring and therapy guide.","Clin Med (Lond)","Tung-Chen, Yale","32398268"],"abstract":["INTRODUCTION: Coronavirus disease 2019 (COVID-19) is a highly contagious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pneumonia and acute respiratory distress syndrome (ARDS) are the most common severe complications. There is growing evidence regarding the imaging findings of COVID-19 in chest X-rays and computed tomography (CT) scans; however, their availability to clinical staff in this pandemic outbreak might be compromised. At this moment, the role of lung ultrasound (LUS) has yet to be explored. The purpose of this case report is to describe the natural course of the disease in mild infection managed at home. CASE REPORT: We report a 35-year-old man with recently diagnosed COVID-19 infection. Clinical examination was unremarkable. The diagnosis of mild disease was made clinically which was later reaffirmed by LUS after identifying a bilateral small pleural effusion and a thickened pleural line. During follow up, subpleural consolidations appeared before symptoms slightly aggravated (cough, tiredness and fever). The patient's condition improved after adjustment of therapy at home. CONCLUSION: LUS is an excellent tool in the characterisation of COVID-19 infection and is more available than CT or X-ray. We emphasise the utility and the opportunity that LUS presents in some clinical scenarios, like this COVID-19 pandemic, and how it may serve as a monitoring and therapy guide."],"journal":"Clin Med (Lond)","authors":["Tung-Chen, Yale"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32398268","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.7861/clinmed.2020-0123","keywords":["covid-19","sars-cov-2","lung ultrasound"],"topics":["Case Report"],"weight":1,"_version_":1666865855056576512,"score":121.761314},{"pmid":32283217,"pmcid":"PMC7151464","title":"Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings.","text":["Mortality of a pregnant patient diagnosed with COVID-19: A case report with clinical, radiological, and histopathological findings.","This report highlights details on a pregnant case of COVID-19 who unfortunately did not survive. This 27-year-old woman at her 30 and 3/7 weeks' gestation was referred to our center with fever, myalgia, and cough. The laboratory investigations showed leukopenia and lymphopenia as well as increased creatinine and CRP levels. The first chest X-ray (faint bilateral patchy opacities) and CT scan (some faint subpleural ground-glass opacities associated with pleural thickening) were not typical for initial COVID-19 pulmonary infection, however, the treatment for COVID-19 was started. Due to respiratory distress, she was intubated and put under mechanical ventilation. After a while, the fetus was born with Apgar score of 0 and did not react to the neonatal cardiopulmonary resuscitation protocol. Finally, due to deterioration in the clinical and imaging findings, the patient was expired as a result of multi-organ failure. Following the death, autopsy was performed and the histopathologic evaluations of the lungs showed evidence of viral pneumonia (viral cytopathic effect and a mild increase in alveolar wall thickness) and ARDS (hyaline membrane). Also, reverse transcription-polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infection in the lungs. To our knowledge, this is the first report of maternal death with confirmed COVID-19 infection.","Travel Med Infect Dis","Karami, Parisa","Naghavi, Maliheh","Feyzi, Abdolamir","Aghamohammadi, Mehdi","Novin, Mohammad Sadegh","Mobaien, Ahmadreza","Qorbanisani, Mohamad","Karami, Aida","Norooznezhad, Amir Hossein","32283217"],"abstract":["This report highlights details on a pregnant case of COVID-19 who unfortunately did not survive. This 27-year-old woman at her 30 and 3/7 weeks' gestation was referred to our center with fever, myalgia, and cough. The laboratory investigations showed leukopenia and lymphopenia as well as increased creatinine and CRP levels. The first chest X-ray (faint bilateral patchy opacities) and CT scan (some faint subpleural ground-glass opacities associated with pleural thickening) were not typical for initial COVID-19 pulmonary infection, however, the treatment for COVID-19 was started. Due to respiratory distress, she was intubated and put under mechanical ventilation. After a while, the fetus was born with Apgar score of 0 and did not react to the neonatal cardiopulmonary resuscitation protocol. Finally, due to deterioration in the clinical and imaging findings, the patient was expired as a result of multi-organ failure. Following the death, autopsy was performed and the histopathologic evaluations of the lungs showed evidence of viral pneumonia (viral cytopathic effect and a mild increase in alveolar wall thickness) and ARDS (hyaline membrane). Also, reverse transcription-polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infection in the lungs. To our knowledge, this is the first report of maternal death with confirmed COVID-19 infection."],"journal":"Travel Med Infect Dis","authors":["Karami, Parisa","Naghavi, Maliheh","Feyzi, Abdolamir","Aghamohammadi, Mehdi","Novin, Mohammad Sadegh","Mobaien, Ahmadreza","Qorbanisani, Mohamad","Karami, Aida","Norooznezhad, Amir Hossein"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283217","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.tmaid.2020.101665","keywords":["acute kidney injury","acute respiratory distress syndrome","coronavirus disease 2019","intrauterine fetal death","pregnancy","sars-cov-2"],"locations":["fever","myalgia"],"e_drugs":["Creatinine"],"topics":["Case Report"],"weight":1,"_version_":1666138491472314368,"score":118.234375}]}